EP4311829 - SUBSTITUTED BICYCLIC HETEROARYL SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF CANCER [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 26.07.2024 Database last updated on 22.08.2024 | |
Former | The application has been published Status updated on 29.12.2023 | Most recent event Tooltip | 26.07.2024 | The date on which the examining division becomes responsible, has been established | 26.07.2024 | Request for examination filed | published on 28.08.2024 [2024/35] | 26.07.2024 | Change - designated states | published on 28.08.2024 [2024/35] | 26.07.2024 | New entry: Renewal fee paid | Applicant(s) | For all designated states Nodus Oncology Limited Alderley Park Macclesfield SK10 4TG / GB | [2024/05] | Inventor(s) | 01 /
WEILER, Sven 4123 Allschwil / CH | 02 /
GAUCHER, Bérangère 4123 Allschwil / CH | 03 /
RADIMERSKI, Thomas 4123 Allschwil / CH | 04 /
KELLENBERGER, Laurenz 4123 Allschwil / CH | [2024/05] | Representative(s) | Haseltine Lake Kempner LLP One Portwall Square Portwall Lane Bristol BS1 6BH / GB | [2024/05] | Application number, filing date | 22187495.1 | 28.07.2022 | [2024/05] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP4311829 | Date: | 31.01.2024 | Language: | EN | [2024/05] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 19.12.2022 | Classification | IPC: | C07D403/06, C07D403/14, C07D417/06, C07D417/14, A61K31/498, A61K31/517 | [2024/05] | CPC: |
C07D403/06 (EP);
C07D403/14 (EP);
C07D417/06 (EP);
C07D417/14 (EP)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2024/35] |
Former [2024/05] | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR | Extension states | BA | Not yet paid | ME | Not yet paid | Validation states | KH | Not yet paid | MA | Not yet paid | MD | Not yet paid | TN | Not yet paid | Title | German: | SUBSTITUIERTE BICYCLISCHE HETEROARYLSULFONAMIDDERIVATE ZUR BEHANDLUNG VON KREBS | [2024/05] | English: | SUBSTITUTED BICYCLIC HETEROARYL SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF CANCER | [2024/05] | French: | DÉRIVÉS D'HÉTÉROARYL SULFONAMIDE BICYCLIQUE SUBSTITUÉS POUR LE TRAITEMENT DU CANCER | [2024/05] | Examination procedure | 23.07.2024 | Amendment by applicant (claims and/or description) | 23.07.2024 | Examination requested [2024/35] | 23.07.2024 | Date on which the examining division has become responsible | Fees paid | Renewal fee | 25.07.2024 | Renewal fee patent year 03 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [A]WO9426722 (DU PONT [US], et al) [A] 15 * Tables *; | [A]WO2016092326 (CANCER REC TECH LTD [GB]) [A] 1-15 * examples 1,109,129; claim 1 *; | [X] - Stoicescu_crivetz, "B C U I A S I", Annales Scientifiques de l'Université de Jassy, vol. 29, (19431207), URL: http://dspace.bcu-iasi.ro/static/web/viewer.html?file=http://dspace.bcu-iasi.ro/bitstream/handle/123456789/54995/Scurte%20comunicari%20originale,%20Revista%20Stiintifica%20V.%20Adamachi,%20An.29,%20Nr.3-4,%201943,%20p.301-310.pdf?sequence=1&isAllowed=y#, (20221207), XP093005657 [X] 15 * RN = 858236-63-2 * | [A] - ABDEL-HAMIDE S. G, GHORAB M. M, EL-HIFNAWI H. N, "Effect of novel biologically active oxadiazino-, oxadiazolo-, and oxathiadiazolo-quinazolinones on non-irradiated and radioresistant Staphylococcus aureus", ACTA PHARNMCEUTICA ZAGREB, (1998), vol. 48, no. 4, pages 249 - 258, XP009541134 [A] 15 * Experimental part, Schemes 1 and 2 * | by applicant | WO9426722 | WO2016092326 | WO2016097749 | WO2021055744 | - GAILLARD H et al., Nature Reviews Cancer, (20150000), vol. 15, no. 5, pages 276 - 89 | - BROWN JS et al., Cancer Discovery, (20170000), vol. 7, no. 1, pages 20 - 37 | - CURTIN NJ, Nature Reviews Cancer, (20120000), vol. 12, no. 12, pages 801 - 17 | - HARTWELL LH et al., Science, (19970000), vol. 278, no. 5340, pages 1064 - 8 | - BRYANT HE et al., Nature, (20050000), vol. 434, no. 7035, pages 913 - 21 | - TURNER N et al., Nature Reviews Cancer, (20040000), vol. 4, no. 10, pages 814 - 9 | - LEUNG AKL, Trends in Cell Biology, (20200000), vol. 30, no. 5, pages 370 - 383 | - BARKAUSKAITE E, Nature Communications, (20130000), vol. 4, page 2164 | - MARQUES M et al., Oncogene, (20190000), vol. 38, no. 12, pages 2177 - 2191 | - PILLAY N et al., Cancer Cell, (20190000), vol. 35, no. 3, pages 519 - 533 | - COULSON-GILMER C et al., Journal of Experimental & Clinical Cancer Research, (20210000), vol. 40, no. 1, page 323 | - PROKHOROVA E et al., Molecular Cell, (20210000), vol. 81, no. 12, pages 2640 - 2655 | - CHEN S-HYU X, Science Advances, (20190000), vol. 5, no. 4, page eaav4340 | - HOUL JH et al., Nature Communications, (20190000), vol. 10, no. 1, page 5654 | - ABDEL-HAMIDE et al., Acta Pharmaceutica (Zagreb, (19980000), vol. 48, no. 4, pages 249 - 258 | - COWLEY GS et al., Scientific Data, (20140000), vol. 1, page 140035 | - PAVE G., Org. Lett., (20150000), vol. 17, pages 4930 - 4932 | - The Journal of Organic Chemistry Guidelines for Authors | - MCDONALD ER et al., Cell, (20170000), vol. 170, no. 3, pages 577 - 592 | - HANAHAN D, Cancer Discovery, (20220000), vol. 12, no. 1, pages 31 - 46 | - HOTTIGER MO et al., Trends in Biochemical Sciences, (20100000), vol. 35, no. 4, pages 208 - 19 | - POURFARJAM Y et al., Biochemical and Biophysical Research Communications, (20200000), vol. 527, no. 3, pages 818 - 823 | - SLADE D, Genes & Development, (20200000), vol. 34, no. 5-6, pages 360 - 394 | - DROWN BS et al., Cell Chemical Biology, (20180000), vol. 25, no. 12, pages 1562 - 1570 | - CHEUNG HW et al., Proceedings of the National Academy of Sciences USA, (20110000), vol. 108, no. 30, pages 12372 - 7 |